Literature DB >> 9103446

Immunoregulatory idiotypes stimulate T helper 1 cytokine responses in experimental Schistosoma mansoni infections.

M A Montesano1, G L Freeman, W E Secor, D G Colley.   

Abstract

Inbred male CBA/J mice with chronic Schistosoma mansoni infections develop two distinct syndromes. Hypersplenomegaly syndrome (HSS) demonstrates pathologic similarities to the hepatosplenic form of chronic human schistosomiasis, and moderate splenomegaly syndrome (MSS) resembles the asymptomatic intestinal form. Immunoaffinity-purified Abs against S. mansoni soluble egg Ags (SEA) from infected patients' sera differ idiotypically according to the donor's clinical form of the disease. We now show that immunoaffinity-purified anti-SEA Abs (Id) from MSS or HSS mice parallel idiotypic preparations of the analogous human clinical form by their differential ability to stimulate the proliferation of anti-Id T cells. MSS Id preparations stimulate spleen cells from either MSS or HSS animals. In contrast, HSS Id does not stimulate spleen cells from either group. In an anti-SEA ELISA, MSS and HSS Id preparations contained comparable levels of IgM and IgG1. However, the MSS Id preparation had higher levels of SEA-specific IgG2a and IgG2b than did HSS Id. The Ig isotypes of these Id preparations suggested differences in cytokine expression patterns. Studies of the cytokine profiles of the spleen cells responding to anti-SEA Id preparations demonstrated that while Id preparations from acutely infected mice stimulate IL-4 and IL-10 production, Id preparations from chronic MSS mice stimulate IFN-gamma production. HSS Id did not stimulate the production of any of these cytokines. The possibility that distinct immunoregulatory environments may contribute to the development of MSS and HSS correlates with earlier hypotheses that hepatosplenic pathology results at least in part from a lack of development or expression of appropriate regulatory Ids.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9103446

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  Murine schistosomiasis as a model for human schistosomiasis mansoni: similarities and discrepancies.

Authors:  Rashad A Abdul-Ghani; Azza A Hassan
Journal:  Parasitol Res       Date:  2010-04-06       Impact factor: 2.289

2.  Dexamethasone, a drug for attenuation of Schistosoma mansoni infection morbidity.

Authors:  Alexandre dos Santos Pyrrho; Juliene Antonio Ramos; Roberto Moura Neto; Célia Santos da Silva; Henrique Leonel Lenzi; Christina Maeda Takiya; Cerli Rocha Gattass
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

3.  Differential Vbeta T-cell receptor usage during chronic experimental schistosomiasis corresponds with distinct pathological presentations.

Authors:  W E Secor; G L Freeman
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

4.  Idiotypes expressed early in experimental Schistosoma mansoni infections predict clinical outcomes of chronic disease.

Authors:  M Angela Montesano; Daniel G Colley; Margaret T Willard; George L Freeman; W Evan Secor
Journal:  J Exp Med       Date:  2002-05-06       Impact factor: 14.307

5.  CD4+ T cell-mediated granulomatous pathology in schistosomiasis is downregulated by a B cell-dependent mechanism requiring Fc receptor signaling.

Authors:  D Jankovic; A W Cheever; M C Kullberg; T A Wynn; G Yap; P Caspar; F A Lewis; R Clynes; J V Ravetch; A Sher
Journal:  J Exp Med       Date:  1998-02-16       Impact factor: 14.307

6.  Development of adult worms and granulomatous pathology are collectively regulated by T- and B-cells in mice infected with Schistosoma japonicum.

Authors:  Hongbin Tang; Zhenping Ming; Rong Liu; Tao Xiong; Christoph G Grevelding; Huifeng Dong; Mingsen Jiang
Journal:  PLoS One       Date:  2013-01-22       Impact factor: 3.240

7.  Neonatal idiotypic exposure alters subsequent cytokine, pathology, and survival patterns in experimental Schistosoma mansoni infections.

Authors:  M A Montesano; D G Colley; S Eloi-Santos; G L Freeman; W E Secor
Journal:  J Exp Med       Date:  1999-02-15       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.